VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Venetoclax and azacitidine for AML ineligible for standard induction

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores the use of venetoclax and azacitidine in older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy, as evaluated in the VIALE-A study (NCT02993523) presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter